3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
6
Lymphoid
2
Gynecologic
2
Thoracic
1
Conditions
Ovarian Neoplasms
1001
Uterine Cervical Neoplasms
418
Endometrial Neoplasms
347
Breast Neoplasms
291
Carcinoma, Non-Small-Cell Lung
290
Neoplasms
238
Colorectal Neoplasms
231
Fallopian Tube Neoplasms
210
Stomach Neoplasms
191
Pancreatic Neoplasms
184
Melanoma
157
Prostatic Neoplasms
151
Triple Negative Breast Neoplasms
146
Carcinoma, Ovarian Epithelial
146
Lung Neoplasms
136
Neoplasm Metastasis
131
Squamous Cell Carcinoma of Head and Neck
129
Carcinoma, Renal Cell
129
Head and Neck Neoplasms
121
Esophageal Neoplasms
120
Urinary Bladder Neoplasms
112
Small Cell Lung Carcinoma
88
Sarcoma
80
Carcinoma, Hepatocellular
75
Recurrence
69
Carcinoma, Transitional Cell
69
Uterine Cervical Dysplasia
66
Papillomavirus Infections
66
Colonic Neoplasms
59
Cholangiocarcinoma
58
Interventions
rucaparib
1
olaparib
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pathologic Complete Response
×
Gynecologic
×
Clear all
NCT01844986
2025-12-10
SOLO-1
AstraZeneca
Phase 3
Active not recruiting
450 enrolled
18 charts
1 FDA
NCT03522246
2025-06-24
ATHENA
pharmaand GmbH
Phase 3
Active not recruiting
1,097 enrolled
26 charts